Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Lexaria Bioscience Corp. (LEXX:NASDAQ), powered by AI.
Lexaria Bioscience Corp. is currently trading at $0.59. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Lexaria Bioscience Corp. on Alpha Lenz.
Lexaria Bioscience Corp.'s P/E ratio is -0.9.
“Lexaria Bioscience Corp. trades at a P/E of -0.9 (undervalued) with modest ROE of -215.9%. 3Y revenue CAGR of 40.3% highlights clear growth momentum.”
Ask for details →Lexaria Bioscience Corp. is a biotechnology company focused on enhancing the delivery of bioactive compounds, including cannabinoids and nicotine, through its proprietary drug delivery platform, DehydraTECH. The primary function of this platform is to improve the speed and efficiency of oral absorption of active pharmaceutical ingredients, with potential applications extending across a wide range of industries, including pharmaceuticals, nutraceuticals, consumer packaged goods, and more. Lexaria's technology aims to provide alternative product formulations that offer improved bioavailability and taste masking without altering the stimulant properties of the active compounds. By operating at the intersection of drug development and consumer health, the company plays a pivotal role in advancing innovative delivery solutions, contributing to the growing market of next-generation wellness products. Lexaria Bioscience Corp. continues to partner with organizations intent on developing products that integrate its advanced technology, seeking to capitalize on emerging markets where efficient delivery systems for bioactive substances are increasingly in demand.
“Lexaria Bioscience Corp. trades at a P/E of -0.9 (undervalued) with modest ROE of -215.9%. 3Y revenue CAGR of 40.3% highlights clear growth momentum.”
Ask for details →Lexaria Bioscience Corp. (ticker: LEXX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 7 employees. Market cap is $11M.
The current price is $0.589 with a P/E ratio of -0.89x and P/B of 3.55x.
ROE is -215.88% and operating margin is -1683.01%. Annual revenue is $705,923.